Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2953–2976 of 6,604 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Multi Center Clear all
Recruiting Phase 1Phase 2 Interventional

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

NCT06425926
View directory record Official record
Conditions
Melanoma Stage IV, Solid Tumor
Interventions
GIM-531, Anti-PD-1 monoclonal antibody
Drug
Lead sponsor
Georgiamune Inc
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Scottsdale, Arizona • Bakersfield, California • Fullerton, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Study of Gulf War Illness (GWI) by Comparing GWI and Healthy Veterans

NCT00810225
View directory record Official record
Conditions
Gulf War Illness, Persian Gulf War Syndrome
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
Not listed
Enrollment
516 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Nov 15, 2026, 1:14 AM EST
Terminated Not applicable Interventional

Evaluation of the CloSys Closure System as an Adjunct to Standard Compression

NCT00963690
View directory record Official record
Conditions
Sealing the Arteriotomy
Interventions
CloSys Hemostatic Device (HD), Standard compression
Device · Procedure
Lead sponsor
CloSys Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Lafayette, Louisiana • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Nov 15, 2026, 1:14 AM EST
Completed Not applicable Interventional

A Study of Isoprinosine in Patients With Lymph Node Disease

NCT00002297
View directory record Official record
Conditions
Lymphatic Disease, HIV Infections
Interventions
Inosine pranobex
Drug
Lead sponsor
Newport Pharmaceuticals International
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 15, 2026, 1:14 AM EST
Completed No phase listed Observational

Geri-TBI: A Prospective Multi-center Evaluation of Geriatric Patients With Traumatic Brain Injury

NCT05171010
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
no study-based therapeutic interventions
Other
Lead sponsor
Methodist Health System
Other
Eligibility
40 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2Phase 3 Interventional

Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)

NCT02637960
View directory record Official record
Conditions
Nocturia
Interventions
Fedovapagon 2 mg, Placebo
Drug
Lead sponsor
Vantia Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Lincoln, California + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 3 Interventional Results available

Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

NCT02558374
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

NCT03196297
View directory record Official record
Conditions
Haemostasis, Haemophilia A
Interventions
Concizumab, Turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Los Angeles, California • Indianapolis, Indiana • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Nov 15, 2026, 1:14 AM EST
Terminated Phase 3 Interventional

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

NCT01555710
View directory record Official record
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
Carboplatin, Palifosfamide-tris, Etoposide
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 4 Interventional Results available

Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine

NCT01248468
View directory record Official record
Conditions
Pain, Migraine
Interventions
Aspirin, acetaminophen and caffeine, Sumatriptan, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Anaheim, California • San Francisco, California • Clearwater, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 1 Interventional

UB-312 in Patients With Synucleinopathies

NCT05634876
View directory record Official record
Conditions
Multiple System Atrophy, Parkinson Disease
Interventions
UB-312 Injection, Placebo Injection
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 1 Interventional

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00040950
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, agatolimod sodium
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

NCT01669174
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Interventions
Placebo, BYM338
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Torrance, California • Savannah, Georgia • Normal, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Nov 15, 2026, 1:14 AM EST
Completed Not applicable Interventional Results available

Using Alternative Implants for the Surgical Treatment of Hip Fractures (The FAITH Study)

NCT00761813
View directory record Official record
Conditions
Femoral Neck Fractures
Interventions
Open reduction internal fixation (ORIF) with single sliding hip screw, ORIF with multiple cancellous screws
Device
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years and older
Enrollment
1,108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2 Interventional

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg LX1033 tablets, Placebo tablet
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2 Interventional Results available

Multiple Doses of AT-1501-A201 in Adults With ALS

NCT04322149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AT-1501
Drug
Lead sponsor
Anelixis Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Nov 15, 2026, 1:14 AM EST
Terminated Phase 2Phase 3 Interventional Results available

Efficacy & Safety of TD-1473 in Ulcerative Colitis

NCT03758443
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Chula Vista, California • La Jolla, California • Lancaster, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Nov 15, 2026, 1:14 AM EST
Terminated Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

NCT00073476
View directory record Official record
Conditions
Stroke
Interventions
traxiprodil (CP-101,606)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
12
States / cities
La Mesa, California • Atlanta, Georgia • Fort Wayne, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2006 · Synced Nov 15, 2026, 1:14 AM EST
Not listed Not applicable Interventional

Evaluate the SENSE Device's Ability to Monitor and Detect Intracranial Hemorrhage

NCT04642443
View directory record Official record
Conditions
Intracranial Hemorrhages, Traumatic Brain Injury
Interventions
SENSE Device
Device
Lead sponsor
Sense Diagnostics, LLC
Industry
Eligibility
22 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 15, 2026, 1:14 AM EST
Completed Not applicable Interventional Results available

Efficiency and Safety of Holmium Laser With Moses Technology Versus SuperPulsed Laser System With Thulium Fiber Laser on Renal Stones

NCT06070714
View directory record Official record
Conditions
Renal Stone
Interventions
Holmium laser with pulse modulation, Thulium fiber laser
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Gamma Frequency Stimulation in Individuals With Down Syndrome

NCT05196984
View directory record Official record
Conditions
Down Syndrome
Interventions
GENUS device (Active Settings), GENUS device (Sham Settings)
Device
Lead sponsor
Massachusetts Institute of Technology
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers

A 4-Arm Efficacy and Safety Study of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124552
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001 Botulinum toxin type A (Dose A), RT001 Botulinum Toxin Type A (Dose B), Vehicle, Placebo
Drug · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Nov 15, 2026, 1:14 AM EST
Completed Phase 3 Interventional

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

NCT00752258
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Mentor Purified Toxin Botulinum Toxin Type A
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Nov 15, 2026, 1:14 AM EST